Skip to main content

Table 4 Characteristics of non-SVR12 patients, n = 5

From: Effectiveness and safety of SOF/VEL containing rescue therapy in treating chronic HCV-GT4 patients previously failed NS5A inhibitors-based DAAs

Treatment received

Age (years)

Gender

Smoking

Alcohol use

Comorbid

Previous treatment

HCV viral load (IU)

Liver cirrhosis

FIB-4

SOF/VEL/VOX

41

Male

Yes

No

HTN

SOF/DCV

74

No

0.76

SOF/VEL/VOX

36

Male

Yes

Yes

none

SOF/DCV

179

No

1.17

SOF/VEL + RBV

65

Male

Yes

No

DM

SOF/DCV + RBV

3680

Yes

4.99

SOF/VEL + RBV

56

Female

No

No

HTN

SOF/DCV + RBV

1,004,000

Yes

3.62

SOF/VEL + RBV

56

Female

No

No

HTN + DM

SOF/DCV + RBV

6,220,000

Yes

4.24

SOF/VEL + RBV

59

Female

No

No

None

SOF/DCV + RBV

281,000

Yes

2.79

  1. aSOF sofosbuvir VEL velpatasvir, VOX voxilaprevir, DCV daclatasvir, RBV ribavirin